Vmbook Online ordering

Islet Sciences Inc

Islet Sciences Inc. (ISLT) is a development-stage biotech company focused on the research, development, and commercialization of cannabinoid-based therapies. The company's main focus is on the development of islet cell transplantation therapies for diabetes.

As of the time of writing, there is no recent financial information available for Islet Sciences Inc. for the most recent fiscal year. However, for the year ended December 31, 2019, the company reported no revenue and a net loss of approximately $740,000.

In terms of growth, it's important to note that Islet Sciences is still in the development stage and has not yet brought any products to market. As a result, the company has yet to generate any significant revenue. However, the global diabetes market is expected to grow at a CAGR of around 9% from 2020 to 2027, according to a report by Fortune Business Insights, which could create significant opportunities for companies like Islet Sciences if they are able to successfully develop and commercialize their therapies.

It's important to note that investing in development-stage biotech companies like Islet Sciences can be risky, and there is no guarantee of success. As with any investment, it's important to conduct thorough research and consider seeking advice from a financial advisor or investment professional.